Details of the Drug Combinations

General Information of This Drug (ID: DM5JVAN)

Drug Name

Fingolimod DM5JVAN

Synonyms

2-Amino-2-(4-octylphenethyl)propane-1,3-diol

Indication

Disease Entry	ICD 11	Status	REF
Multiple sclerosis	8A40	Approved	[1]
Primary progressive multiple sclerosis	8A40.1	Approved	[2]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2	[3]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

3 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Citalopram + Fingolimod	DC9UVNM	Citalopram	Depression	[4]
Fluoxetine + Fingolimod	DCBH6WG	Fluoxetine	Depression	[4]
Venlafaxine + Fingolimod	DCH97QT	Venlafaxine	Depression	[4]
------------------------------------------------------------------------------------

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2407).
3	ClinicalTrials.gov (NCT04280588) Fingolimod in COVID-19
4	ClinicalTrials.gov (NCT01436643) Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression